Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

(2017) Jan-Patrick Stellmann et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study

(2017) M. Cohen et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Ocrelizumab in multiple sclerosis: markers and mechanisms

(2017) Reinhard Hohlfeld et al.   LANCET NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination

(2016) Michael A. Maurer et al.   JOURNAL OF NEUROIMMUNOLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders

(2016) Valentina Damato et al.   JAMA Neurology

Rituximab does not reset defective early B cell tolerance checkpoints

(2015) Nicolas Chamberlain et al.   JOURNAL OF CLINICAL INVESTIGATION

Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response

(2015) Diana G. Adlowitz et al.   PLoS One

Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity

(2012) Michael A. Maurer et al.   JOURNAL OF CLINICAL INVESTIGATION

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success

(2012) Benjamin M Greenberg et al.   Multiple Sclerosis Journal

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years

(2011) Su-Hyun Kim   ARCHIVES OF NEUROLOGY

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders

(2011) Klaus Lehmann-Horn et al.   Journal of Neuroinflammation

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

(2011) H. L. Pellkofer et al.   NEUROLOGY

Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis

(2011) Nancy L. Monson et al.   PLoS One

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

(2010) Martin S. Weber et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Échec thérapeutique du rituximab dans un cas de neuromyélite optique rémittente : suivi prospectif longitudinal sur deux ans

(2008) C. Cassinotto et al.   REVUE NEUROLOGIQUE